MEOBF vs SPHDF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MEOBF is a Buy and SPHDF is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MEOBF’s FA Score shows that 0 FA rating(s) are green whileSPHDF’s FA Score has 0 green FA rating(s).
- MEOBF’s FA Score: 0 green, 5 red.
- SPHDF’s FA Score: 0 green, 5 red.
Price Growth
MEOBF (@Biotechnology) experienced а -5.41% price change this week, while SPHDF (@Biotechnology) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +2.10%. For the same industry, the average monthly price growth was -5.02%, and the average quarterly price growth was +3.97%.
Reported Earning Dates
MEOBF is expected to report earnings on Feb 20, 2025.
Industries' Descriptions
@Biotechnology (+2.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| MEOBF | SPHDF | MEOBF / SPHDF | |
| Capitalization | 1.1B | 108M | 1,022% |
| EBITDA | -62.82M | N/A | - |
| Gain YTD | 529.874 | 0.000 | - |
| P/E Ratio | N/A | N/A | - |
| Revenue | 5.9M | N/A | - |
| Total Cash | 62.6M | N/A | - |
| Total Debt | 119M | N/A | - |
MEOBF | SPHDF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 93 | 39 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 94 | 100 | |
PRICE GROWTH RATING 1..100 | 35 | 70 | |
P/E GROWTH RATING 1..100 | 68 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SPHDF's Valuation (68) in the null industry is in the same range as MEOBF (89). This means that SPHDF’s stock grew similarly to MEOBF’s over the last 12 months.
SPHDF's Profit vs Risk Rating (100) in the null industry is in the same range as MEOBF (100). This means that SPHDF’s stock grew similarly to MEOBF’s over the last 12 months.
MEOBF's SMR Rating (94) in the null industry is in the same range as SPHDF (100). This means that MEOBF’s stock grew similarly to SPHDF’s over the last 12 months.
MEOBF's Price Growth Rating (35) in the null industry is somewhat better than the same rating for SPHDF (70). This means that MEOBF’s stock grew somewhat faster than SPHDF’s over the last 12 months.
MEOBF's P/E Growth Rating (68) in the null industry is in the same range as SPHDF (100). This means that MEOBF’s stock grew similarly to SPHDF’s over the last 12 months.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
MEOBF and
Correlation & Price change
A.I.dvisor indicates that over the last year, MEOBF has been loosely correlated with SPHDF. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MEOBF jumps, then SPHDF could also see price increases.
| Ticker / NAME | Correlation To MEOBF | 1D Price Change % | ||
|---|---|---|---|---|
| MEOBF | 100% | +8.25% | ||
| SPHDF - MEOBF | 50% Loosely correlated | N/A | ||
| AVTX - MEOBF | 46% Loosely correlated | -11.47% | ||
| COGT - MEOBF | 39% Loosely correlated | -1.10% | ||
| MESO - MEOBF | 26% Poorly correlated | -1.45% | ||
| KROS - MEOBF | 26% Poorly correlated | -0.55% | ||
More | ||||
SPHDF and
Correlation & Price change
A.I.dvisor indicates that over the last year, SPHDF has been closely correlated with TRML. These tickers have moved in lockstep 78% of the time. This A.I.-generated data suggests there is a high statistical probability that if SPHDF jumps, then TRML could also see price increases.
| Ticker / NAME | Correlation To SPHDF | 1D Price Change % | ||
|---|---|---|---|---|
| SPHDF | 100% | N/A | ||
| TRML - SPHDF | 78% Closely correlated | -5.33% | ||
| COGT - SPHDF | 63% Loosely correlated | -1.10% | ||
| MEOBF - SPHDF | 50% Loosely correlated | +8.25% | ||
| KROS - SPHDF | 38% Loosely correlated | -0.55% | ||
| CYTO - SPHDF | 35% Loosely correlated | -0.55% | ||
More | ||||